UNSPSC 51433901: Efonidipine

This classification denotes a calcium channel blocker with the molecular formula C34H38N3O7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40ZTP2T37Q, chemically known as 2-(n-benzylanilino)ethyl (- )-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester. but generally known as efonidipine, which bears US NIH Compound Identifier 119171. European Medicines Agency schedules Efonidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06471MIG.

UNSPSC 51433901 Efonidipine, a Commodity code, describes a single pharmaceutical product — a calcium channel blocker medication — that state and local governments procure primarily through emergency medical services departments and state health agencies managing pharmacy benefit programs. Recent activity shows procurement focused on two distinct pathways: direct supply contracts for emergency responder medications and cooperative purchasing arrangements for generic pharmaceuticals distributed across multiple state and local health facilities. The code sits at the intersection of emergency preparedness and population health procurement, with issuing bodies ranging from municipal fire rescue departments to state health and human services commissions operating through multistate cooperative purchasing vehicles.

The geographic mix reflects activity in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing the most structured recent opportunity. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking 1,020 units of Diltiazem 25mg vials (among other cardiac and emergency medications) with a nine-month minimum shelf life and delivery within ten calendar days, under a one-year term with two optional renewals; the estimated contract value was $40,000.00 and included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in early April 2026 to explore direct-to-manufacturer pharmacy programs, signaling exploratory procurement before formal solicitation. MMCAP's RFP S1070000015802, posted January 20, 2026 with responses due March 26, 2026, establishes multistate contracts for generic and OTC pharmaceuticals across participating state and local facilities in Minnesota and Oregon through authorized wholesalers, with awards effective July 1, 2026 and a two-year initial term. Pricing evaluation under the MMCAP RFP weights price competitiveness at 75 percent, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and minimum insurance coverage of $5,000,000 general liability.